TD Cowen initiated coverage of Bio-Techne (TECH) with a Buy rating and $65 price target The pullback and multiple de-rating look overdone, even though macro risks have weighed on shares, the analyst tells investors in a research note. The current valuation doesn’t reflect the strong organic growth and margin opportunity where Bio-Techne addresses several of the highest growth areas in Tools with strong product offerings, TD Cowen adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne: Undervalued Stock with Strong Growth Potential and Margin Expansion Opportunities
- Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy
- Airbnb, Zscaler downgraded: Wall Street’s top analyst calls
- Bio-Techne price target lowered to $65 from $90 at Argus
- Bio-Techne: Strong Market Position and Growth Potential Justify Buy Rating